Nektar CEO Opens Door To Finance Questions In Eli Lilly Trial
Nektar Therapeutics failed Wednesday to block evidence of its financial condition from entering into a California federal trial over a failed deal to codevelop its drug Rezpeg with Eli Lilly, after...To view the full article, register now.
Already a subscriber? Click here to view full article